Do Not Prescribe EzPAP as a Universal "Wellness Program" for Your Chronic Trach/Vent Population
You should not implement blanket EzPAP therapy across your chronic tracheostomy and ventilator unit, and you cannot bill Medicare for this device as a preventive "wellness program" in this population. The evidence does not support universal application of positive expiratory pressure devices in chronically ventilated patients with hypoxic brain injury or stroke, and Medicare does not cover respiratory devices for wellness or prevention—only for specific medical indications with documented therapeutic need.
Why This Approach Is Problematic
Wrong Population for the Evidence Base
The recent studies showing EzPAP efficacy are in acute COPD exacerbations 1, 2, not chronic ventilator-dependent patients with neurological injury. The 2025 RCT by comparing EzPAP to NIV demonstrated improved pH correction and reduced hospital admissions specifically in mild-to-moderate hypercapnic COPD exacerbations 1. Your facility has "just a couple with COPD" and mostly patients with hypoxic brain damage or stroke—this is a fundamentally different population.
The physiological study in healthy adults 3 showed EzPAP increases tidal volume and generates positive pressures, but this was tested in people with normal respiratory mechanics and intact neurological function, not brain-injured patients on chronic mechanical ventilation.
Tracheostomy Changes the Equation
For patients with tracheostomies, the evidence actually supports individualized PEEP application for specific purposes like improving speech 4, not blanket therapy. That study showed patient-controlled PEEP at median 10 cmH₂O improved phonation in neuromuscular patients, but this was:
- Titrated individually to each patient's needs
- Under patient control for comfort
- For a specific therapeutic goal (communication)
- In neuromuscular disease, not hypoxic brain injury
Brain-Injured Patients Require Different Considerations
The 2025 narrative review on brain-protective ventilation 5 emphasizes that ventilator management in acute brain injury (including stroke and hypoxic-ischemic encephalopathy) must be individualized to preserve intracranial pressure and cerebral perfusion pressure. While moderate PEEP can be used safely with concurrent cerebral monitoring 6, 7, this requires:
- Active monitoring of ICP and CPP
- Titration based on individual cerebral physiology
- Integration with multimodal neuromonitoring
A blanket "wellness program" approach contradicts these principles entirely.
What the Guidelines Actually Say
The 2025 Portuguese guidelines 8 specify home mechanical ventilation indications for:
- COPD: Persistent PaCO₂ ≥52 mmHg in stable disease
- Neuromuscular disease: As adjunct to airway clearance therapy
- Bronchiectasis/CF: Stable persistent hypercapnia or bridge to transplant
The 2015 British Thoracic Society guidelines 9 explicitly state that patients with neuromuscular weakness or established ventilatory failure should receive NIV support, not isolated positive pressure therapy.
None of these guidelines support prophylactic positive pressure devices for chronic ventilator patients without specific indications.
The Medicare Billing Problem
Medicare does not cover respiratory devices for:
- "Wellness programs"
- Prevention in the absence of documented disease
- Blanket application without individual medical necessity
To bill for any respiratory device, you need:
- Specific diagnosis codes indicating medical necessity
- Documentation of therapeutic goals
- Evidence of patient-specific need
- Demonstration that the device addresses an active medical problem
Attempting to bill Medicare for EzPAP as preventive therapy in patients already on chronic mechanical ventilation would likely be considered inappropriate billing.
The Appropriate Clinical Approach
Consider EzPAP or similar devices only for specific indications:
COPD patients with acute hypercapnic exacerbations (you have "just a couple")
Neuromuscular patients needing airway clearance augmentation (you have 3-4)
- As adjunct to cough assist and therapy vest
- When secretion management is inadequate with current therapy
- Based on 8
Individual patients with documented need for improved speech (trach patients)
- Titrate PEEP individually
- Allow patient control
- Based on 4
Do not use for:
- Chronic hypoxic brain injury patients on stable ventilation
- Stroke patients without specific respiratory indication
- "Wellness" or prevention in already-ventilated patients
How to Respond to Administration
Your response should clarify:
The facilities without trachs/vents have different patient populations where preventive respiratory therapy might be appropriate (e.g., post-surgical patients at risk for atelectasis, ambulatory COPD patients)
Your patients are already on maximal ventilatory support—adding another device without specific indication doesn't constitute "keeping patients healthy"
Evidence-based medicine requires matching interventions to patient populations—the studies supporting EzPAP are in acute COPD exacerbations, not chronic vent-dependent neurological patients
Medicare compliance requires individual medical necessity—you cannot bill for blanket "wellness" programs with durable medical equipment
You are willing to use EzPAP for appropriate indications when individual patients meet evidence-based criteria
Common Pitfalls to Avoid
- Don't confuse "doing something" with "doing something beneficial"—adding interventions without evidence can increase patient discomfort, staff burden, and infection risk
- Don't let corporate protocols override clinical judgment—facilities without physicians may implement programs that seem reasonable but lack medical appropriateness for specific populations
- Don't assume devices safe in one population are universally applicable—brain-injured patients have unique vulnerabilities regarding ICP and cerebral perfusion
- Don't bill Medicare for services that don't meet medical necessity criteria—this creates compliance risk for you and the facility
Your opposition is medically sound and should be maintained. Offer to develop evidence-based protocols for appropriate EzPAP use in the small subset of patients who might benefit, but resist blanket implementation.